Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Merger or Acquisition (January 2022)
37 slides from Observe Medical ASA's merger presentation, Jan 14, 2022
Slide 1: Observe Medical Company Presentation
OBSERVE MEDICAL Company Presentation 14 January 2022
Slide 2: Disclaimer and important information
COMPANY PRESENTATION Disclaimer and important information The information materials in this presentation (the "Presentation") have been produced by Observe Medical ASA (the "Company", and together with its consolidated subsidiaries the "Group") solely for information purposes in connection with the
Slide 3: Introduction
INTRODUCTION
Slide 4: Presenting team
INTRODUCTION Presenting team Björn Larsson Per Arne Nygård Rune Nystad Chief Executive Officer Chief Financial Officer Chief Executive Officer, Biim 25+ years of experience from 20+ years of experience from finance 20+ years of experience from global medtech, pharma and biotech and accounting in var
Slide 5: The new Observe Medical
INTRODUCTION The new Observe Medical Attractive medtech platform further strengthened via game-changing acquisition of Biim Business overview Financial performance Key facts • Observe Medical is a Nordic based medtech Revenue (MNOK) 25 platform with global reach 20 Headquarters • Commercializing pro
Slide 6: Nordic-based medtech platform with established global reach
INTRODUCTION Nordic-based medtech platform with established global reach PLATFORM ▪ Solid platform for growth, commercializing proprietary innovative medtech products on a global market by organic growth and targeted M&A ▪ International distributor and partner network and Nordic direct sales operati
Slide 7: A true international medtech platform
INTRODUCTION A true international medtech platform Access to a high-quality global distribution network Partnerships with leading global distributors International sales footprint OM Biim Both Potential via partners1 Strong reach and well connected with Italian opinion leaders within ICU and urine m
Slide 8: Financial performance
INTRODUCTION Financial performance Revenue (MNOK) Historical performance Pro forma revenue bridge (2020) 25 20 41.3% 10 gross 8 margin 13 12 3 3 0 2019 2020 Q3’21 YTD Observe Medical1 Sylak2 Biim Pro forma Revenue mix Q3’21 YTD Commentary • In October 2020, Observe Medical acquired Sylak AB, a Swedi
Slide 9: Key investment highlights
INTRODUCTION Key investment highlights 1 Powerful medtech commercialization platform Commercializing proprietary innovative products to capitalize on significant market opportunities Biim acquisition accelerates commercial roll-out of combined portfolio 2 Complementary distribution networks and mark
Slide 10: Acquisition Rationale
ACQUISITION RATIONALE
Slide 11: Biim acquisition rationale – Three key reasons
ACQUISITION RATIONALE Biim acquisition rationale – Three key reasons Expanding product portfolio Adjacent verticals offer similar end-customers, enabling cross-selling, improved patient welfare, health economics and data accuracy Extending distribution network Complementary distribution networks and
Slide 12: Expanding product portfolio
ACQUISITION RATIONALE Expanding product portfolio Adjacent verticals offer similar end-customers, enabling cross-selling, improved patient welfare, health economics and data accuracy Sippi® Biim Ultrasound The first automated and wireless Intuitive, wireless and digital urine meter for ICUs and pock
Slide 13: Extending distribution network
ACQUISITION RATIONALE Extending distribution network Complementary distribution networks and market insights combined to drive pace of commercialization Contact established with multitude of global and Nordic direct sales Sweden multinational distributors Beneficial Regional complementary Finland Ho
Slide 14: Extracting operational synergies
ACQUISITION RATIONALE Extracting operational synergies Similar functions can be streamlined, cross-utilized or centralized Connectivity solutions Supply chain Admin & processes Centralized expertise for Streamlined processes and management high quality and reduced overhead costs Higher working capit
Slide 15: Biim Ultrasound
BIIM ULTRASOUND
Slide 16: Biim at a glance – An international medical ultrasound technology company
BIIM ULTRASOUND Biim at a glance – An international medical ultrasound technology company Company introduction Presence Biim’s ultrasound technology in 3 countries Biim’s wireless pocketable ultrasound device allow for the ability to Headquarter in Narvik, Norway scan patients and review images in s
Slide 17: Biim's unique ultrasound probe stands out among competitors
BIIM ULTRASOUND Biim’s unique ultrasound probe stands out among competitors Biim delivers a unique device… … which clearly stands out among its competitors Ultrasound made-simple concept Higher level of complexity adding An intuitive and low Wireless performance challenges complexity device devices
Slide 18: Extensive R&D since 2014 – agreement with Fresenius a major milestone
BIIM ULTRASOUND Extensive R&D conducted since 2014 – agreement with Fresenius a major important milestone Product and App Market introduction and 3-year distribution Revenue reached Second product LOI signed in May Pilot study involving development period FDA approval agreement secured 1.1m USD laun
Slide 19: The dialysis market opens for a huge potential for Biim
BIIM ULTRASOUND The dialysis market opens for a huge potential for Biim The market potential within dialysis is huge Fresenius partnership opens extensive growth opportunities Fresenius Kabi is a global healthcare company specializing in lifesaving There are In the global market there medicines and
Slide 20: Significant untapped potential in adjacent market segments
BIIM ULTRASOUND Significant untapped potential for Biim to distribute their product in adjacent market segments Similar medical segments …where Biim has already established partnerships Dialysis Centres Vascular Access Teams ▪ A global provider of industry-leading medical devices used to treat cance
Slide 21: Sippi®
SIPPI®
Slide 22: Sippi® solves one of the last manual monitoring procedures in the ICU
SIPPI® Sippi® solves one of the last manual monitoring procedures in the ICU Addressing key burdens of current clinical practice, A unique, automated, digital urine meter with wireless representing considerable added value and cost savings data transfer and biofilm control Burdens of current Patient
Slide 23: Sippi® overview and functionality
SIPPI® Sippi® Base unit Sippi® overview and functionality • Sippi® is the first automated digital urine meter with biofilm control and wireless connectivity, initially sold to ICUs and wards • Current generation of Sippi®, with wireless connectivity to patient data monitoring systems, launched in Q4
Slide 24: Significant market potential for Sippi® with strong volume growth
SIPPI® Significant market potential for Sippi® with strong volume growth Current global market potential Further potential for optimizing hospital implementation Current focus: ~400k ~0.5M Hospital ICU beds Sippi® base units Thoracic dept. 1 surgery 8 beds: 24M +30M BU1: 10 Hospital admitted to ICU
Slide 25: Sippi® provides significant clinical and economic value for ICUs
SIPPI® Sippi® provides significant clinical and economic value for ICUs Reduced infection risk factors Time and efficiency gains Improved data for clinical decisions 2.5 million Healthcare Acquired Infections (HAI) in EU Time consuming manual recording of urine output on Suboptimal measurement accur
Slide 26: Outlook
OUTLOOK
Slide 27: Outlook
OUTLOOK Outlook Multiple key milestones in the short and medium term, providing a highly attractive medtech story for shareholders Commercial development Market access & IP Clinical roll-out Ambitions Integrate Vygon's tip location Targeting market clearance Rolling out the Biim unit to Sales of 500
Slide 28: Appendix
APPENDIX
Slide 29: Management and Board of Directors
APPENDIX Management and Board of Directors Management Björn Larsson Per Arne Nygård Mikael Löfgren Jenny Wennerberg Chief Executive Officer Chief Financial Officer CTO/COO QA & RA Director Board of Directors Terje Bakken Sanna Rydberg Kathrine Gamborg Andreassen Thomas Grünfeld Chairman of the Board
Slide 30: Largest shareholders and company structure
APPENDIX Largest shareholders Company structure1 # Shareholder # shares % shares Country Observe Medical ASA 1 NAVAMEDIC ASA 4,222,727 21.54% Norway (Norway) 2 INGERØ REITEN INV. COMPANY AS 3,939,394 20.09% Norway 3 RO, LARS 1,501,051 7.66% Norway Observe Medical ApS 100% 4 UBS SWITZERLAND AG 1,418,
Slide 31: Sippcoat® and Sippsense® - two-stage microbial transportation reduction
APPENDIX Sippcoat® and Sippsense® - a two-stage microbial transportation reduction 1 Sippcoat® zone ▪ The Sippcoat® treated zone acts as a temporary barrier for biofilm formation ▪ Microbial transportation is thereby reduced 2 Biofilm indicator ▪ If biofilm builds up, Sippsense® alerts 31
Slide 32: Three scientific articles supporting clinical value of Sippi®
APPENDIX Three scientific articles have been published Protected by IPR supporting the clinical value of Sippi® portfolio 1) A. Eklund, M. Slettengren & Jan van der Linden (2015) Performance and user evaluation of a novel ▪ The Sippi® global patent situation is capacitance-based automatic urinometer
Slide 33: Key figures – Profit and loss statement
APPENDIX Key figures – Profit and loss statement Amount in TNOK YTD Q3'21 Q3 2021 Q3 2020 FY 2020 FY 2019 PF 2020 Operating revenues 20,452 7,606 9 2,961 177 25,449 Cost of materials 12,004 3,940 5 1,975 637 12,891 Gross result 8,448 3,665 4 986 -460 12,559 Employee benefit expenses 14,336 5,914 2,0
Slide 34: Key figures – Statement of financial position (I/II)
APPENDIX Key figures – Statement of financial position (I/II) Amount in TNOK Q3 2021 Q3 2020 FY 2020 FY 2019 PF 2020 ASSETS Non-current assets Goodwill 34,746 33,736 36,268 30,333 162,210 Intangible assets 19,531 21,625 20,965 20,997 106,002 Tangible assets 1,669 48 703 339 5,958 Total non-current a
Slide 35: Key figures – Statement of financial position (II/II)
APPENDIX Key figures – Statement of financial position (II/II) Amount in TNOK Q3 2021 Q3 2020 FY 2020 FY 2019 PF 2020 EQUITY AND LIABILITIES Total equity 2,608 40,327 20,349 14,542 205,349 Non-current liabilities Non-current lease liabilities 882 9 260 78 3,266 Contingent consideration 12,794 14,099
Slide 36: Key figures – Cash flow statement
APPENDIX Key figures – Cash flow statement Amount in TNOK YTD Q3'21 Q3 2021 Q3 2020 FY 2020 FY 2019 Cash flow from operating activities Result before tax -11,928 -8,444 -5,856 -36,868 -16,917 Depreciation and impairment 2,463 847 787 3,163 4,285 Change in net finance, no cash effect -10,282 870 448
Slide 37: a Keonserve
a Keonserve medical
Observe Medical — Merger or Acquisition (January 2022) on 6ix